Treatment | Mean PFS at 20Â months* | 95% CrI | Mean PFS at 40Â months* | 95% CrI |
---|---|---|---|---|
Tamoxifen | 6.71 | (5.31; 8.29) | 7.05 | (5.48; 9.11) |
Exemestane | 8.36 | (4.55; 12.63) | 9.04 | (4.60; 16.47) |
CD | 7.97 | (5.00; 11.91) | 7.98 | (5.00; 12.50) |
MA | 7.18 | (4.51; 10.38) | 7.42 | (4.54; 11.85) |
CMF | 10.14 | (5.85; 15.76) | 10.23 | (5.85; 20.36) |
Mitoxantrone | 7.71 | (3.43; 13.03) | 7.91 | (3.43; 16.01) |
Docetaxel | 7.92 | (4.37; 12.45) | 7.93 | (4.37; 13.30) |
Doxorubicin | 7.35 | (3.96; 12.09) | 7.36 | (3.96; 12.80) |
Epirubicin | 6.16 | (2.53; 12.17) | 6.16 | (2.53; 12.96) |
Capecitabine | 9.90 | (5.03; 16.67) | 9.96 | (5.04; 22.43) |
Paclitaxel | 7.10 | (3.78; 11.90) | 7.11 | (3.78; 12.50) |
PLD | 7.14 | (3.09; 13.56) | 7.15 | (3.09; 15.12) |
Nab paclitaxel | 10.10 | (5.42; 15.75) | 10.15 | (5.42; 18.33) |
Liposomal doxorubicin | 6.66 | (3.12; 12.00) | 6.66 | (3.12; 12.38) |
Vinorelbine | 7.55 | (2.99; 14.28) | 7.60 | (2.99; 17.71) |
Exemestane + Everolimus | 12.21 | (6.21; 16.98) | 14.14 | (6.25; 26.72) |
Tamoxifen + Everolimus | 10.85 | (5.16; 15.59) | 13.62 | (5.36; 24.79) |